Multiply Labs develops robotic systems for the life sciences industry, with a particular focus on manufacturing cell therapies. The company's technology applies robotics and artificial intelligence to automate complex, manual pharmaceutical production processes, addressing a critical scalability challenge in personalized medicine.
Its core product consists of modular robotic clusters - systems where multiple collaborative robot arms operate in parallel. These are engineered to produce both personalized pharmaceutical capsules and cell therapies at scale. According to the company, this approach reduces manufacturing costs by 74% while significantly increasing production throughput.
The firm operates at the intersection of automation, AI, and life sciences, targeting the pharmaceutical and cell therapy manufacturing verticals. Its work centers on enabling the large-scale production of precision medicines that are traditionally difficult and costly to manufacture.
